High Purity New England (HPNE), a supplier of solutions and equipment for the biopharmaceutical industry, has received a $15 million contract from the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services. This contract has been issued to expand and accelerate the production of pharmaceutical consumables, including single-use assemblies, single-use pumps, single-use mixing systems, and sterile individually packaged components. In return, HPNE will provide preferred pricing and precedence for orders from BARDA and BARDA 3rd parties issued in response to a Presidential Declaration of Public Health Emergency.

Specifically, the contract* will be used to open the company’s fourth facility near their three other buildings, expanding on what is becoming a campus in northern Rhode Island. This facility will expand manufacturing capacity and supports the previously mentioned single-use products. The new building will include state-of-the-art cleanrooms, further software and data tools, as well as numerous support facilities including additional office space, production support, and logistics areas.

The company, located about 45 minutes south of Boston, has continued to grow over the past 3 years, and this contract will amplify that development by supporting and strengthening the company’s manufacturing output. This will also help expedite development of their new product offerings, shorten their lead times and increase jobs in the local community.

As the industry needs grow, High Purity New England continues to supply the biopharma and biotech industries with a range of innovative products—from drug discovery and development to fill-finish, including their flagship product, custom single-use assemblies, as well as pumps, mixers, and other single-use solutions. Along with their own manufactured products for the global market, they are also a distributor for 18 brands in North America and proudly supports numerous companies working on vaccines and therapeutics in the fight against COVID-19.

*This project has been funded in whole or in part with federal funds from the Biomedical Advanced Research and Development Authority (BARDA), Assistant Secretary for Preparedness and Response (ASPR), Department of Health and Human Services (HHS), under contract number 75A50122C00009.